Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Vertex pharmaceuticals - The Untold Story

What to Expect From Vertex Pharmaceuticals’ Q1 2026 Earnings Report

Vertex Pharmaceuticals is set to report its first-quarter results next month, and analysts are expecting high single-digit growth in earnings.

Barchart

Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Vertex Pharmaceuticals’ stock has lagged behind the broader market over the past year, but analysts remain moderately bullish about its prospects.

Barchart

Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report

Vertex Pharmaceuticals is scheduled to post its fourth-quarter results soon, and analysts project a double-digit earnings growth

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Vertex's Gene Therapy Works In Children With Blood Disorders

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Saturday presented data from multiple studies demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in patients aged 5 years and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).

Benzinga

Earnings Preview: What To Expect From Vertex Pharmaceuticals' Report

Vertex Pharmaceuticals is set to post its third-quarter results next month, and analysts project a single-digit earnings drop.

Barchart

ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” on Thursday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes ServiceNow, Inc. (NYSE:NOW), which is down 14% year-to-date.

Benzinga

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

Is Vertex Pharmaceuticals Stock Underperforming the S&P 500?

Vertex Pharmaceuticals has lagged the broader S&P 500 Index over the past year, but Wall Street analysts remain moderately optimistic about the company’s long-term prospects.

Barchart

Do Wall Street Analysts Like Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has significantly underperformed the broader market over the past year, yet analysts remain optimistic about the stock’s prospects.

Barchart

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported better-than-expected earnings for the second quarter after the market close on Monday.

Benzinga

Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported financial results for the second quarter after the market close on Monday. Here’s a rundown of the report.

Benzinga

Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release earnings results for the second quarter, after the closing bell on Monday, Aug. 4.

Benzinga

How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks?

Vertex Pharmaceuticals has outperformed its biotech peers over the past year, yet Wall Street analysts maintain a reasonably optimistic outlook on its future potential.

Barchart

Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

While Vertex Pharmaceuticals has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Vertex Pharmaceuticals’ Q1 2025 Earnings: What to Expect

Vertex Pharmaceuticals is set to unveil its Q1 results in the upcoming month, and analysts expect a double-digit drop in earnings.

Barchart

Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?

Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.

LiveScience

FDA approves 1st new class of opioid-free painkillers in over 20 years

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Vertex's Pain Drug: Big Pharma's Next Major Success?

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

Barchart

Vertex Pharmaceuticals Earnings Preview: What to Expect

With Vertex Pharmaceuticals gearing up to release its fourth-quarter earnings next month, analysts predict a single-digit drop in profit.

Fortune

20 innovative breakthroughs that will transform your health

We recognize some of the most staggering, game-changing, life-improving developments of the year.

Benzinga

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts

In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX), offering a diverse range of perspectives from bullish to bearish.

Barchart

Is Vertex Pharmaceuticals Stock Underperforming the Dow?

Despite Vertex Pharmaceuticals’ recent underperformance compared to the Dow Jones, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?

Vertex Pharmaceuticals has outperformed the Nasdaq over the past year, and analysts remain moderately bullish about the stock's prospects.

Barchart

Are Wall Street Analysts Bullish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market in 2024 but Wall Street analysts remain cautiously bullish about the stock's potential.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

65 stories

63 stories

Regeneron Pharmaceuticals

63 stories

Vertex Pharmaceuticals

58 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.